JP Morgan Maintains Overweight on NeuroPace, Raises Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Robbie Marcus has maintained an Overweight rating on NeuroPace (NASDAQ:NPCE) and increased the price target from $9 to $17.
March 12, 2024 | 1:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Robbie Marcus has reaffirmed an Overweight rating on NeuroPace and raised the price target from $9 to $17.
The increase in price target by a reputable analyst like Robbie Marcus from JP Morgan is a strong positive signal for NeuroPace. It suggests a bullish outlook on the company's future performance and potential for stock price appreciation. This kind of endorsement can lead to increased investor confidence and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100